About Low molecular weight phosphotyrosine protein phosphatase
Low molecular weight phosphotyrosine protein phosphatase (ACP1) is a protein
from Homo sapiens identified by UniProt accession
P24666, 158 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Low molecular weight phosphotyrosine protein phosphatase |
|---|
| UniProt accession | P24666 |
|---|
| Gene | ACP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 158 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (120)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- high density lipoprotein cholesterol measurement · score 0.30
- body height · score 0.30
- low molecular weight phosphotyrosine protein phosphatase measurement · score 0.27
- body mass index · score 0.26
- refractive error · score 0.26
- apolipoprotein A 1 measurement · score 0.26
- blood protein measurement · score 0.23
- serum urea measurement · score 0.22
- C-reactive protein measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P24666-F1 | alphafold | PREDICTED | 96.08 | — |
Amino-acid sequence (158 residues)
MAEQATKSVL FVCLGNICRS PIAEAVFRKL VTDQNISENW RVDSAATSGY EIGNPPDYRG QSCMKRHGIP MSHVARQITK EDFATFDYIL CMDESNLRDL NRKSNQVKTC KAKIELLGSY DPQKQLIIED PYYGNDSDFE TVYQQCVRCC RAFLEKAH
Explore Low molecular weight phosphotyrosine protein phosphatase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets